Search results
Results From The WOW.Com Content Network
Experimental Hematology is a peer-reviewed medical journal of hematology, which publishes original research articles and reviews, as well as the abstracts of the annual proceedings of the Society for Hematology and Stem Cells (formerly known as the International Society for Experimental Hematology). The journal is published monthly by Elsevier ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
ISO 4 (Information and documentation — Rules for the abbreviation of title words and titles of publications) is an international standard which defines a uniform system for the abbreviation of serial publication titles, i.e., titles of publications such as scientific journals that are published in regular installments.
This is a list of journals and their associated Bluebook abbreviation. The list is based on the entries explicitly listed in the 19th edition. Entries with a (18) are found in the 18th edition, but not the 19th.
Biomarkers is a peer-reviewed academic journal covering research on biomarkers. It is published by Taylor & Francis and the editor-in-chief is Martin Möckel ( Charité ). According to the Journal Citation Reports , the journal has a 2015 impact factor of 2.016.
Haematologica is a monthly peer-reviewed open access medical journal published by the Ferrata Storti Foundation. The editor-in-chief is Jacob M. Rowe (Rambam Medical Center, Haifa, Israel). The journal covers all topics related to experimental and clinical hematology. It was established in 1920 by Adolfo Ferrata.
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."
One example of a prognostic biomarkers in clinical research, is the use of mutated PIK3CA in the study of metastatic breast cancer. As illustrated by the graph , the mutation is prognostic since its presence in the patient endure the same outcome regardless of the treatment method used.